GUMDROP : A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and ADT in Men with Non-Metastatic Prostate Cancer and a Rising PSA After Primary Therapy

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial measures the level of response of the immune system following different sequences of sipuleucel-T and androgen deprivation therapy in prostate cancer patients who have undergone definitive local therapy (surgery and-or radiation) and who have with PSA doubling time = 12 months, non-metastatic cancer, testosterone = 200 ng/dL. Patients are exclude if they have prior androgen deprivation therapy of at least 6 month duration; prior denosumab, radiation or androgen deprivation therapy in the last 6 months; chemotherapy in the prior 90 days. 

Link:

http://clinicaltrials.gov/ct2/show/NCT01431391

Site:

Johns Hopkins University

Principal Investigator:

Emmanuel Antonarakis, M.D.